Advertisement
"We look forward to the contributions of Ms. Eastham and Dr. McCarthy asmembers of the Genoptix Board of Directors. Each bring their individualexpertise in their fields and personal style of leadership, adding diversityof opinion and further strengthening the leadership of the company as we moveforward," said Dr. Tina Nova Bennett, president and CEO of Genoptix.
Advertisement
Karin Eastham has served as the Executive Vice President, Chief OperatingOfficer, and Trustee for the Burnham Institute for Medical Research since2004. Prior to this, Ms. Eastham was the Senior Vice President of Finance andthe Chief Financial Officer for Diversa Corporation. She has also served insimilar senior level management roles at Combichem, Inc., Cytel Corporationand Boehringer Mannheim Diagnostics. She currently serves on the Boards ofDirectors for multiple life science companies including Illumina, Inc., andAmylin Pharmaceuticals, Inc. She also serves on the boards of Tercica, Inc.and SGX Pharmaceuticals, Inc., which have entered into definitive mergeragreements pursuant to which such companies will be acquired by Ipsen, S.A.and Eli Lilly and Company, respectively, subject to various conditionsincluding stockholder approval. Ms. Eastham earned her MBA in Finance andB.S. in Accounting from Indiana University and is a member of the AmericanInstitute of Certified Public Accountants and the California Society ofCertified Public Accountants. Ms. Eastham is also a Certified Director.
Laurence R. McCarthy, Ph.D., is a Venture Partner with Ampersand Venturesand President of Scientific Technologies and Solutions, LLC. Dr. McCarthy wasPresident, CEO, Chairman and CTO of Focus Diagnostics and later served as itsCTO following the company's acquisition by Quest Diagnostics. Prior to this,he was President for the U.S. Diagnostics Division of Boehringer Mannheim andVice President and General Manager and Vice President R&D for Becton Dickinson& Co. Dr. McCarthy's academic experience includes faculty positions at JohnsHopkins School of Medicine, University of North Carolina School of Medicine,and Cornell University School of Medicine, as well as serving as a LaboratoryDirector at the Memorial Sloan-Kettering Cancer Center and at the NorthCarolina Memorial Hospital. Dr. McCarthy received his Ph.D. in Microbiologyfrom the University of New Hampshire and his B.S. in Biology from St. AnselmCollege.
These additions bring the total number of members serving on the Genoptix,Inc. board to nine. They join Genoptix, Inc. president and CEO Tina NovaBennett, Ph.D., board chairman Andrew Senyei, M.D., Robert Curry, Ph.D.,Timothy Buono, Michael Henos, Arda Minocherhomjee, Ph.D., and Thomas Waltz,M.D.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused ondelivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad,California.
Forward-Looking Statements
This press release contains forward-looking statements that are subject torisks and uncertainties that could cause actual results to differ materiallyfrom those set forth in the forward-looking statements. Actual results maydiffer materially from those projected. Genoptix disclaims, however, an
